METTL1 and intrahepatic cholangiocarcinoma: In a preclinical mouse model of intrahepatic cholangiocarcinoma (ICC), PD-1 treatment simultaneously blocked METTL1 and its downstream chemokine pathway (CXCL8 in the human body and CXCL5 in the mouse body), boosting the immune response in the mice [224].